1 – 10 of 16
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care
(
- Contribution to journal › Article
-
Mark
Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor : results from 13 European registries
(
- Contribution to journal › Article
-
Mark
Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis : Results From the European Spondyloarthritis Research Collaboration Network
(
- Contribution to journal › Article
-
Mark
Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice
(
- Contribution to journal › Article
- 2023
-
Mark
Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis : results from five Nordic biologics registries
(
- Contribution to journal › Article
-
Mark
Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe
(
- Contribution to journal › Scientific review
-
Mark
Sex differences in the effectiveness of first-line tumour necrosis factor inhibitors in axial spondyloarthritis : Results from the EuroSpA Research Collaboration Network
(
- Contribution to journal › Article
-
Mark
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis : 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial
(
- Contribution to journal › Article
- 2022
-
Mark
Outpatient Use of Antimicrobials in Patients With Rheumatoid Arthritis Before and After Treatment With Tumor Necrosis Factor Inhibitors : A Nationwide Retrospective Cohort Study
(
- Contribution to journal › Article
-
Mark
Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs : Results from four Nordic countries
(
- Contribution to journal › Article